Loading Events

« All Events

Applying Clinical Evidence to Practice: DOPTELET® (avatrombopag) for Adult Patients with Chronic Immune Thrombocytopenia (ITP) Who Have Had an Insufficient Response to a Previous Treatment

April 29 @ 5:30 pm - 6:30 pm

DOPTELET® (avatrombopag) is indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment.

Target Audience:
This educational activity is directed toward medical oncologists, pathologists, surgical oncologists, and other clinicians involved in the management of cancer patients. 

Cost:
This event is complementary to MOASC Members but registration is required. 

More details Here

Register here

Details

Date:
April 29
Time:
5:30 pm - 6:30 pm
Event Category:

Venue

Webinar
Website:
[email protected]

Organizer

DOVA Pharmaceuticals